Pharma Equity Group A/S

PEG A

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-12 am EDT			5-day change	1st Jan Change
0.29 ^DKK	-2.68%		+15.08%	-32.56%

May. 17	Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 16	Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	CI

Blue Vision A/S : 231 Financial Calendar 29-12-2016 nr.25

January 02, 2017 at 10:27 am EST

Date: 29. December 2016 Company announcement no.: 25

Page 1 of 1.

BLUE VISION A/S - Financial calendar for 2017

Please find below the financial calendar for 2017:

31. March 2017 Public announcement of the Annual Report for 2016

28. April 20167 Ordinary general meeting for 2016

25. August 2017 Public announcement of the Interim Report for the 2ndquarter 2017

30. March 2017 Public announcement of the Annual Report for 2017

27. April 2017 Ordinary general meeting for 2017

Best regards. Blue Vision A/S

Niels Troen Chairman

Blue Vision A/S Philip Heymans Allé 3, 1 DK-2900 Hellerup

Blue Vision A/S published this content on 02 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 January 2017 15:27:03 UTC.

Original documenthttp://www.blue-vision.dk/images/FInanskalender/Finanskalender2017Engelsk.pdf

Public permalinkhttp://www.publicnow.com/view/4722FDBF2839E36993E2495253BD23E9F5B7BCD7

Latest news about Pharma Equity Group A/S

Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	May. 16	CI
Pharma Equity Group A/S announced that it expects to receive DKK 1 million in funding	May. 15	CI
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	Apr. 09	CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	Apr. 05	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024	Mar. 20	CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding	Feb. 06	CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding	Jan. 24	CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office	Jan. 22	CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding	Jan. 21	CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Jan. 17	CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial	Nov. 16	MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial	Nov. 16	CI
Pharma Equity Group A/S Approves Board Appointments	Nov. 02	CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition	23-10-31	CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method	23-08-15	MT
Pharma Equity Group A/S Announces Board Changes	23-06-15	CI
Reponex Pharmaceuticals A/S Announces CEO Changes	23-06-14	CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer	23-06-14	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S.	23-03-23	CI

Chart Pharma Equity Group A/S

Duration

Period

More charts

Company Profile

Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.

Sector

Investment Holding Companies

Calendar

2024-08-15 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Holding Companies

	1st Jan change	Capi.
PHARMA EQUITY GROUP A/S	-32.56%	43.36M
INVESTOR AB	+27.39%	85.99B
KOÇ HOLDING	+62.20%	17.65B
INVESTMENT AB LATOUR	+15.33%	18.36B
AB INDUSTRIVÄRDEN	+7.57%	14.45B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+29.06%	13.19B
L E LUNDBERGFÖRETAGEN AB	-1.31%	12.74B
HAL TRUST	-0.53%	11.15B
MERITZ FINANCIAL GROUP INC.	+38.75%	10.99B
SK SQUARE CO., LTD.	+100.19%	10.22B